Health Evolution Partners

GROWTH AND LATE STAGE INVESTMENTS

Health Evolution Partners has allocated $500M to growth and late stage investments. Our strategies for growth and late stage investing include:

Invest in successful businesses that have the potential to become market leaders in their industry sector
Focus investments on health care services, information and technology that improve value to end users
Partner with strong management teams who want to work with us to enhance company growth and value
Work with purchasers and industry leaders to accelerate uptake of portfolio company products, services and solutions

Health Evolution Partners is making growth and late stage investments in companies that are EBITDA positive, or that have a demonstrated pathway to EBITDA growth. Our investments are for expansion, growth, recapitalization, buyouts, spin-offs and other forms of late-stage financing. We focus on companies with sustainable competitive advantages in the health care economy. Our target investments have strong management teams, proprietary health care technology and processes, and desire an active partner to help build value.

We are selective in our investments; and spend considerable time working with portfolio companies. Consequently, we prefer equity investments with initial commitments in the range of $10M to $80M.

For more information read Health Evolution Partners Investment Strategy, or contact us at:
investments@healthevolutionpartners.com.

EARLY STAGE INVESTMENTS

Health Evolution Partners Innovation Network (HEPIN) is an investment fund aimed at early stage and venture companies. Through HEPIN, Health Evolution Partners will invest up to $100M into partner funds, and may co-invest another $100M into portfolio companies alongside partner funds.

Funds that are eligible to participate in the HEPIN must:

Principally invest in the health care industry
Invest only a minority of funds into life sciences
Focus exclusively on early stage and venture companies
Demonstrate a track record of excellent performance

HEPIN has completed investments in two venture funds to date:

Cardinal Partners has been one of the leading venture capital partnerships focused exclusively on health care investing since 1996. Cardinal specializes in early stage financing rounds, usually as the lead investor in the initial financing round of a growth company. Since 1997, companies funded by Cardinal have a cumulative market valuation exceeding $6 billion. Cardinal currently manages funds totaling $330M.
Psilos Group, founded in 1998, is a health care-focused venture capital firm which invests in the health care services, health care information technology and medical technology sectors. With more than $500M under management, Psilos invests in companies that demonstrate the ability to reduce health care system costs while improving quality of care, and the ability to align the incentives of patients, payers and providers.

HEP has also invested in Prematics, Inc., an innovative provider of turn-key, fully managed electronic prescribing services that removes common barriers to physician adoption. Prematics’ exceptional management team is led by Kevin Hutchinson, Chief Executive Officer, and James Bradley, Chairman of the Board. Prior to joining Prematics, Hutchinson was the founding president and CEO of SureScripts, considered the gold standard for pharmacy interoperability and the routing of electronic prescriptions. Bradley was the founding CEO of RxHub, a healthcare technology company formed by the nation's three largest pharmacy benefit managers. The Prematics solution, ScriptTone, operates on the company's proprietary end-to-end network and enables physicians to choose the most clinically appropriate and cost-effective prescriptions.

For more information read Health Evolution Partners Innovation Network, or contact us at:
fundpartnerships@healthevolutionpartners.com.